8 results about "Amylin" patented technology

Disclosed herein is a 4-phenyl-lH-pyrazolo[3,4-b]pyridine-5- carboxamide derivative of formula (I) as amylin and / or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight.

The present invention relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, by administering petrelintide at a high dose. The invention also relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, in a human female subject, by administering a non-incretin peptide hormone.

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

Compounds useful in the treatment or prevention of diabetes and related conditions and in the prevention, inhibition or reversal of amylin-amyloid fiber formation, the prevention of Langerhans island (beta) cell death, the prevention or reversal of the conversion of soluble human amylin to insoluble human amylin, the prevention and inhibition or reversal of cytotoxic amylin fiber formation. The present invention relates to compounds of formula (I): (I).

Peptides exhibiting amylin and calcitonin receptor (DACRA) agonist activity, as well as prodrug derivatives thereof, are provided. Analogues with enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided, as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising the peptide analogues and therapeutic methods of use of the peptide analogues are also provided.

The present application relates to compounds of Formula I, which modulate calcitonin receptor and / or amylin receptor activity and are useful in the treatment of bone, metabolic, cardiovascular, neurodegenerative and other disorders. I

Methods for detecting or quantifying amylin-beta amyloid (Aβ) hetero-oligomers (amylin-Aβ aggregate) are provided. Anti-amylin and anti-Aβ antibodies which recognize epitopes that are distinct from high affinity binding sites between amylin peptide and Aβ peptide can be utilized as capture and detection antibodies, respectively, in a sandwich enzyme-linked immunosorbent assay (ELISA) to provide detection and quantification of amylin-Aβ aggregate present in a biological sample, such as blood or brain tissue. Kits useful for the detection and the quantification of amylin-Aβ aggregate are also provided.

The invention relates to the technical field of therapeutic cyclopeptide-containing polypeptides, in particular to a cyclopeptide-containing polypeptide compound, application of the cyclopeptide-containing polypeptide compound and a long-acting amylin medicine. The polypeptide compound containing the cyclic peptide is selected from the following compounds shown in the following structural formula: R < 1-gamma > Glu-Arg-Asp-Gly-Thr-Ala-Thr-Lys-Ala-Thr-Glu-Arg-Leu-Ala-X < 15 >-X < 16 >-X < 17 >-Gln-Arg-Ser-Ser-X < 22 >-X < 23 >-X < 24 >-X < 25 >-X < 26 >-Ser-X < 28 >-Thr-Glu-Val-Gly-Sr-Asn-Thr-{Hyp}-NH2 (Lactm bridge: Asp < 3 >-Lys8), and the structural formula of the polypeptide compound containing the cyclic peptide is shown in the description, (Lactm bridge: Asp3-Lys8) represents an intramolecular lactam bridge formed between side chains of residues of a third amino acid Asp and an eighth amino acid Lys which are counted from an R1 end; r1 represents that R2 is independently selected from any one of a carboxyl group, a carboxylate group, a tetrazolyl group, a phosphate group, a phosphate group, a sulfonic acid group and a sulfonate group; n is any integer from 10 to 24; x < 15 >, X < 16 >, X < 17 >, X < 22 >, X < 23 >, X < 24 >, X < 25 >, X < 26 > and X < 28 > are respectively and independently selected from amino acids. As an amylin drug with a novel structure, the amylin derivative is a multi-target drug and has relatively good biological activity and bioavailability.